Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Technol Cancer Res Treat ; 11(3): 221-8, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22468993

ABSTRACT

Involvement of a cranial nerve caries a poor prognosis for many malignancies. Recurrent or residual disease in the trigeminal or facial nerve after primary therapy poses a challenge due to the location of the nerve in the skull base, the proximity to the brain, brainstem, cavernous sinus, and optic apparatus and the resulting complex geometry. Surgical resection caries a high risk of morbidity and is often not an option for these patients. Stereotactic radiosurgery and radiotherapy are potential treatment options for patients with cancer involving the trigeminal or facial nerve. These techniques can deliver high doses of radiation to complex volumes while sparing adjacent critical structures. In the current study, seven cases of cancer involving the trigeminal or facial nerve are presented. These patients had unresectable recurrent or residual disease after definitive local therapy. Each patient was treated with stereotactic radiation therapy using a linear accelerator based system. A multidisciplinary approach including neuroradiology and surgical oncology was used to delineate target volumes. Treatment was well tolerated with no acute grade 3 or higher toxicity. One patient who was reirradiated experienced cerebral radionecrosis with mild symptoms. Four of the seven patients treated had no evidence of disease after a median follow up of 12 months (range 2-24 months). A dosimetric analysis was performed to compare intensity modulated fractionated stereotactic radiation therapy (IM-FSRT) to a 3D conformal technique. The dose to 90% (D90) of the brainstem was lower with the IM-FSRT plan by a mean of 13.5 Gy. The D95 to the ipsilateral optic nerve was also reduced with IM-FSRT by 12.2 Gy and the D95 for the optic chiasm was lower with FSRT by 16.3 Gy. Treatment of malignancies involving a cranial nerve requires a multidisciplinary approach. Use of an IM-FSRT technique with a micro-multileaf collimator resulted in a lower dose to the brainstem, optic nerves and chiasm for each case examined.


Subject(s)
Cranial Nerve Neoplasms/radiotherapy , Dose Fractionation, Radiation , Facial Nerve , Radiosurgery/methods , Trigeminal Nerve , Aged , Aged, 80 and over , Cranial Nerve Neoplasms/pathology , Facial Nerve/pathology , Facial Nerve/radiation effects , Follow-Up Studies , Head/diagnostic imaging , Humans , Male , Middle Aged , Radiography , Radiotherapy, Intensity-Modulated/methods , Remission Induction , Risk Assessment , Trigeminal Nerve/pathology , Trigeminal Nerve/radiation effects
2.
Gynecol Oncol ; 104(3): 691-4, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17137617

ABSTRACT

PURPOSE: To report our recent experience managing four patients with brain metastases of gestational trophoblastic neoplasia (GTN), coordinating systemic chemotherapy with early neurosurgical intervention or stereotactic radiosurgery and intensive supportive care during initial therapy to prevent early mortality. MATERIALS AND METHODS: A series of four consecutive patients with brain metastases from high-risk Stage IV GTN managed at our institution in 2003 and 2005. Patients were assigned FIGO stage and risk score prospectively. Because of concern for chronic toxicity resulting from concurrent moderate dose methotrexate and whole brain radiation, an individualized multidisciplinary approach was used to manage patients. RESULTS: All four women presented with brain and pulmonary metastases; one had multiple liver metastases. Neurological symptoms at presentation included grand mal seizures in 2 patients, left upper extremity hemiparesis and headache each in 1 patient, while 1 patient was asymptomatic. Index pregnancies were term pregnancies in all patients with interval from prior delivery ranging from 2 weeks to 4 years. Two had received prior chemotherapy for postmolar GTN prior to the index pregnancy with incomplete follow-up. Initial hCG values ranged from 26,400 to 137,751 mIU/ml; FIGO risk scores were > or =16 for all patients. Systemic combination chemotherapy was initiated with etoposide and cisplatin followed by moderate/high-dose (500-1000 mg/m(2)) methotrexate combinations. Craniotomy was used before or during the first chemotherapy cycle to extirpate solitary lesions in 3 patients, while stereotactic radiosurgery was administered after the first cycle to treat two brain lesions in the remaining patient. None received whole brain radiation or intrathecal methotrexate. In one patient, selective angiographic embolization was used to control hemorrhage from multiple liver metastases. Two patients required ventilator support early in treatment to allow stabilization from intrathoracic hemorrhage and neutropenic sepsis with respiratory distress syndrome, respectively. Hysterectomy was performed in one patient after completion of salvage chemotherapy. All have completed maintenance chemotherapy and are in prolonged remission (12-24 months). Neurologic sequelae include persistent left upper extremity dyskinesia and weakness in one patient, and episodic grand mal seizures and pseudoseizures in a second patient with a pre-existing seizure disorder. CONCLUSION: This case series documents the utility for a multidisciplinary approach to the treatment of brain metastases from GTN. Using early craniotomy or stereotactic radiosurgery combined with etoposide-cisplatin and moderate/high-dose methotrexate combination chemotherapy, we were able to stabilize patients early in their treatment and avoid whole brain radiation therapy or intrathecal chemotherapy.


Subject(s)
Brain Neoplasms/secondary , Brain Neoplasms/therapy , Gestational Trophoblastic Disease/pathology , Gestational Trophoblastic Disease/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Choriocarcinoma/pathology , Choriocarcinoma/secondary , Choriocarcinoma/therapy , Cisplatin/administration & dosage , Craniotomy , Cyclophosphamide/administration & dosage , Dactinomycin/administration & dosage , Etoposide/administration & dosage , Female , Folic Acid/administration & dosage , Humans , Methotrexate/administration & dosage , Neoplasm Staging , Pregnancy , Radiosurgery , Risk Factors , Vincristine/administration & dosage
3.
Br J Cancer ; 93(12): 1350-5, 2005 Dec 12.
Article in English | MEDLINE | ID: mdl-16288305

ABSTRACT

Tumour hypoxia has been shown to increase mutation rate, angiogenesis, and metastatic potential, and decrease response to conventional therapeutics. Improved tumour oxygenation should translate into increased treatment response. Exogenous recombinant erythropoietin (rEpo) has been recently shown to increase tumour oxygenation in a mammary carcinoma model. The mechanism of this action is not yet understood completely. The presence of Epo and its receptor (EpoR) have been demonstrated on several normal and neoplastic tissues, including blood vessels and various solid tumours. In addition, rEpo has been shown in two recent prospective, randomized clinical trials to negatively impact treatment outcome. In this study, we attempt to characterize the direct effects of rEpo on tumour growth and angiogenesis in two separate rodent carcinomas. The effect of rEpo on R3230 rat mammary adenocarcinomas, CT-26 mouse colon carcinomas, HCT-116 human colon carcinomas, and FaDu human head and neck tumours, all of which express EpoR, was examined. There were no differences in tumour growth or proliferation (measured by Ki-67) between placebo-treated and rEpo-treated tumours. In the mammary window chamber, vascular length density (VLD) measurements in serial images of both placebo-treated and Epo-treated rats revealed no difference in angiogenesis between the Epo-treated tumours and placebo-treated tumours at any time point. These experiments are important because they suggest that the recent clinical detriment seen with the use of Epo is not due to its tumour growth effects or angiogenesis. These studies also suggest that further preclinical studies need to examine rEpo's direct tumour effects in efforts to improve the therapeutic benefits of Epo in solid tumour patients.


Subject(s)
Carcinoma/pathology , Cell Proliferation/drug effects , Colonic Neoplasms/pathology , Erythropoietin/pharmacology , Head and Neck Neoplasms/pathology , Mammary Neoplasms, Animal/pathology , Neovascularization, Pathologic , Animals , Cell Hypoxia , Humans , Mice , Placebos , Random Allocation , Rats , Recombinant Proteins , Tumor Cells, Cultured
4.
Int J Radiat Oncol Biol Phys ; 59(3): 822-33, 2004 Jul 01.
Article in English | MEDLINE | ID: mdl-15183486

ABSTRACT

PURPOSE: Tumor hypoxia is associated with less effective radiation-mediated cell killing, increased metastatic potential, and poorer prognosis. Transient variations in hypoxia, with characteristic periodicity on the order of 1 to 10 min, have been observed in animal models. This article explores the effect of these temporal variations in PO(2) on the oxygen enhancement ratio, effective radiation dose to the tumor, and tumor control probability. METHODS AND MATERIALS: PO(2) over a 50-60 min period was determined at multiple sites in rat fibrosarcomas, 9L gliomas, and R3230Ac mammary adenocarcinomas. Using a correlation derived from the data of Elkind et al. (1965), PO(2) data are converted into oxygen enhancement ratios (OERs.) A tumor is assumed to consist of 10(3)-10(4) independent oxygenation subvolumes, each with a randomly chosen starting point on the OER-time curve. The effect of temporal variations in OER is examined for three cases: conventionally fractionated external beam radiotherapy (EBRT), stereotactic radiosurgery (SRS) and intraoperative radiotherapy (IORT). The oxygen effective dose (OED) for a subvolume is calculated from the dose to that subvolume modified by the OER. In turn, the distribution of OED for a tumor is analyzed for each treatment case and representative tumor control probabilities (TCPs) calculated. RESULTS: Oxygen enhancement ratio varied from 1 to 3 over the range of PO(2) measured in this study. Mean OER ranged from 1.6 to 2.6, and the variation in OER vs. time was greater with decreasing PO(2). In EBRT, the standard deviation in OED was small, <2%. In contrast, the standard deviation in OED was much higher for both SRS and IORT, typically ranging from 3 to 6%, with the greatest variation at the lowest PO(2)s. Compared with a tumor with equal mean OED and uniform PO(2), TCP was minimally poorer for either EBRT or well-oxygenated tumors. However, for both SRS and IORT, temporal variations in more hypoxic tumors can produce a significant decrease in TCP. CONCLUSION: Temporal variations in tumor PO(2) can produce significant variations OER, particularly at low PO(2), resulting in decreased TCP for hypofractionated treatment regimens.


Subject(s)
Cell Hypoxia/physiology , Neoplasms/physiopathology , Oxygen/metabolism , Radiation Tolerance , Algorithms , Animals , Dose Fractionation, Radiation , Dose-Response Relationship, Radiation , Female , Intraoperative Period , Neoplasms/metabolism , Neoplasms/radiotherapy , Partial Pressure , Radiosurgery , Rats , Rats, Inbred F344 , Time Factors
6.
Thromb Haemost ; 42(5): 1483-9, 1980 Feb 29.
Article in English | MEDLINE | ID: mdl-6892735

ABSTRACT

Cytochalasin B alters the structure and functional properties of filamentous actin. Platelet-mediated clot retraction in dilute platelet-rich plasma (PRP) is inhibited progressively at cytochalasin B concentrations of 0.01 mg/ml, 0.05 mg/ml and 0.1 mg/ml. Dynamic rheological measurements of recalcified PRP in a Weissenberg Rheogoniometer indicate that platelet contractility (as reflected in measurements of elastic moduli) is reduced by 33%, 57% and 63% at cytochalasin B concentrations of 0.01, 0.05 and 0.1 mg/ml, respectively. In contrast, pre-incubation of human platelet-rich plasma (PRP) with 0.01 mg/ml or 0.05 mg/ml cytochalasin B does not inhibit collagen-induced [14C]serotonin release on collagen-induced-platelet aggregation, which is dependent on the release of ADP from platelet dense granules. Even at a cytochalasin B concentration of 0.1 mg/ml, collagen-induced [14C-]serotonin release and aggregation are impaired only moderately. Cytochalasin B does not interfere with the uptake by platelets of [14C-]-serotonin, or with the kinetics and extent of clot formation in platelet-free plasma. Thus, concentrations of cytochalasin B which impair platelet contractility do not inhibit the release of platelet dense granule contents. It is concluded that neither the platelet release reaction nor platelet aggregation is dependent on platelet contractile mechanisms.


Subject(s)
Blood Coagulation/drug effects , Blood Platelets/drug effects , Cytochalasin B/pharmacology , Platelet Aggregation/drug effects , Actins/metabolism , Adenosine Diphosphate/pharmacology , Animals , Cattle , Collagen/pharmacology , Cytoplasmic Granules/drug effects , Fibrin , Humans , Serotonin/metabolism , Thrombin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...